Secreted protein acidic and rich in cysteine-induced cellular senescence in colorectal cancers in response to irinotecan is mediated by P53

Carcinogenesis

Volumn 31, Issue 5, 2010, Pages 812-819

  Chan, Justin M ^a,b   Ho, Shirley H ^a,b   Tai, Isabella T ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; IRINOTECAN; OSTEONECTIN; PROTEIN P53; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL SYNCHRONIZATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; GENE INDUCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CELL AGING; COLORECTAL TUMOR; DNA DAMAGE; DRUG EFFECT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL AGING; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA DAMAGE; HUMANS; MICE; OSTEONECTIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952297767     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq034     Document Type: Article

References (50)

1. Prabhudesai, S.G. et al. (2007) Apoptosis and chemo-resistance in colorectal cancer. J. Surg. Oncol., 96, 77-88.
2. Han, Z. et al. (2002) Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem., 277, 17154-17160.
3. Bates, S. et al. (1996) p53 in signaling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev., 6, 12-18.
4. Hayflick, L. (1974) The strategy of senescence. Gerontologist, 14, 37-45.
5. Dimri, G.P. et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA, 92, 9363-9367.
6. Kortlever, R.M. et al. (2006) Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat. Cell Biol., 8, 877-884.
7. Herbig, U. et al. (2004) Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell, 14, 501-513.
8. Olsen, C.L. et al. (2002) Raf-1-induced growth arrest in human mammary epithelial cells is p16-independent and is overcome in immortal cells during conversion. Oncogene, 21, 6328-6339.
9. Dimri, G.P. et al. (2000) Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol. Cell. Biol., 20, 273-285.
10. Sasaki, M. et al. (2008) Proinflammatory cytokine-induced cellular senescence of biliary epithelial cells is mediated via oxidative stress and activation of ATM pathway: a culture study. Free Radic. Res., 42, 625-632.
11. Lee, B.J. et al. (2005) Effects of cisplatin, 5-fluorouracil, and radiation on cell cycle regulation and apoptosis in the hypopharyngeal carcinoma cell line. Chemotherapy, 51, 103-110.
12. Ewald, J. et al. (2008) Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo. Br. J. Cancer, 98, 1244-1249.
13. Chen, J. et al. (2008) Stress-induced premature senescence of endothelial cells. J. Nephrol., 21, 337-344.
14. Bartkova, J. et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 434, 864-870.
15. Shiloh, Y. (2003) ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer, 3, 155-168.
16. Pantoja, C. et al. (1999) Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene, 18, 4974-4982.
17. Nakagawa, H. et al. (2007) Inducing cellular senescence using defined genetic elements. Methods Mol. Biol., 371, 167-178.
18. Ohtani, N. et al. (2001) Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature, 409, 1067-1070.
19. Jacobs, J.J. et al. (1999) The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature, 397, 164-168.
20. Rheinwald, J.G. et al. (2002) A two-stage, p16(INK4A)-and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol. Cell. Biol., 22, 5157-5172.
21. Ben-Porath, I. et al. (2005) The signals and pathways activating cellular senescence. Int. J. Biochem. Cell Biol., 37, 961-976.
22. Jacobs, J.J. et al. (2000) Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet., 26, 291-299.
23. Schmitt, C.A. et al. (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell, 109, 335-346.
24. Tai, I.T. et al. (2005) Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest., 115, 1492-1502.
25. Tang, M.J. et al. (2007) A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J. Biol. Chem., 282, 34457-34467.
26. Yiu, G.K. et al. (2001) SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol., 159, 609-622.
27. Funk, S.E. et al. (1991) The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc. Natl Acad. Sci. USA, 88, 2648-2652.
28. Baker, S.J. et al. (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 249, 912-915.
29. Comi, P. et al. (1995) Senescence-dependent regulation of type 1 plasminogen activator inhibitor in human vascular endothelial cells. Exp. Cell Res., 219, 304-308.
30. Kurose, A. et al. (2005) Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis. Cytometry A, 68, 1-9.
31. Minderman, H. et al. (2005) In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol. Cancer Ther., 4, 885-900.
32. De Angelis, P.M. et al. (2006) Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol. Cancer, 5, 20.
33. Kim, W.Y. et al. (2006) The regulation of INK4/ARF in cancer and aging. Cell, 127, 265-75.
34. te Poele, R.H. et al. (2002) DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res., 62, 1876-1883.
35. Bertheau, P. et al. (2008) TP53 status and response to chemotherapy in breast cancer. Pathobiology, 75, 132-139.
36. Bossi, G. et al. (2007) Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck, 29, 272-284.
37. Bhonde, M.R. et al. (2006) Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Oncogene, 25, 165-175.
38. Siliciano, J.D. et al. (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev., 11, 3471-3481.
39. Vial, E. et al. (2000) Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors. Oncogene, 19, 5020-5029.
40. Chamboredon, S. et al. (2003) v-Jun downregulates the SPARC target gene by binding to the proximal promoter indirectly through Sp1/3. Oncogene, 22, 4047-4061.
41. Maclaren, A. et al. (2003) v-Jun stimulates both cdk2 kinase activity and G1/S progression via transcriptional repression of p21 CIP1. Oncogene, 22, 2383-2395.
42. Rempel, S.A. et al. (2001) SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J. Neurooncol., 53, 149-160.
43. Esposito, I. et al. (2007) Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia, 9, 8-17.
44. Francki, A. et al. (2003) SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling. J. Cell Biochem., 88, 802-811.
45. Hampel, B. et al. (2004) Differential regulation of apoptotic cell death in senescent human cells. Exp. Gerontol., 39, 1713-1721.
46. Rebbaa, A. et al. (2003) Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene, 22, 2805-2811.
47. Seluanov, A. et al. (2001) Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. Mol. Cell. Biol., 21, 1552-1564.
48. Seoane, J. et al. (2002) Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature, 419, 729-734.
49. Nelyudova, A. et al. (2007) By blocking apoptosis, Bcl-2 in p38-dependent manner promotes cell cycle arrest and accelerated senescence after DNA damage and serum withdrawal. Cell Cycle, 6, 2171-2177.
50. Xue, W. et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 445, 656-660.